68Ga-PSMA PET/CT: Does it predict adverse pathology findings at radical prostatectomy?
CONCLUSION: In patients with intermediate/high-risk prostate cancer, 68Ga-PSMA PET/CT provides information regarding intraprostatic tumor location, SVI and LNI but has no role in assessment for EPE. This information might be useful for pretreatment counseling, decision-making and possibly preoperative planning. PMID: 31204017 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - June 13, 2019 Category: Urology & Nephrology Authors: Dekalo S, Kuten J, Mabjeesh NJ, Beri A, Even-Sapir E, Yossepowitch O Tags: Urol Oncol Source Type: research

Surgical removal of renal tumors with low metastatic potential based on clinical radiographic size: A systematic review of the literature.
CONCLUSION: A substantial portion of patients with SRM are undergoing surgical excision despite harboring tumors of low metastatic potential. The rate of high-grade histology increased with increasing clinical radiographic size, which can be used in counseling and decision-making regarding placement on active surveillance. The number of low-risk SRM removed annually in the United States increased from 8,500 in 2000 to 13,600 in 2014 with stabilization in recent years. PMID: 31202730 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - June 12, 2019 Category: Urology & Nephrology Authors: Patel HD, Semerjian A, Gupta M, Pavlovich CP, Johnson MH, Gorin MA, Allaf ME, Pierorazio PM Tags: Urol Oncol Source Type: research

Prognostic significance of antihypertensive agents in men with castration-resistant prostate cancer.
CONCLUSIONS: Use of antihypertensive agents has prognostic significance for patients with CRPC treated with ARAT agent, but not docetaxel. PMID: 31202731 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - June 12, 2019 Category: Urology & Nephrology Authors: Shiota M, Kobayashi T, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Eto M Tags: Urol Oncol Source Type: research

A preoperative nomogram to predict major complications after robot assisted partial nephrectomy (UroCCR-57 study).
e of Urologic Oncology (CCAFU) Abstract OBJECTIVE: To generate a nomogram based on preoperative parameters to predict the occurrence of a major complication within 30-days of robotic partial nephrectomy. MATERIALS AND METHODS: The study included 1,342 patients with a clinically localized renal tumor who underwent robotic partial nephrectomy (RPN) between 2010 and 2017 at 7 academic centers. The primary outcome was the major complication rate. A multivariable logistic regression model was fitted to predict the risk of major complications after RPN. Model-derived coefficients were used to calculate the risk of ...
Source: Urologic Oncology - June 8, 2019 Category: Urology & Nephrology Authors: Khene ZE, Peyronnet B, Bernhard JC, Kocher NJ, Vaessen C, Doumerc N, Pradere B, Seisen T, Beauval JB, Verhoest G, Roumiguié M, De la Taille A, Bruyere F, Roupret M, Mejean A, Mathieu R, Shariat S, Raman JD, Bensalah K, members of the French Committee of Tags: Urol Oncol Source Type: research

TRIM24 as an independent prognostic biomarker for prostate cancer.
CONCLUSION: Using 2 large independent radical prostatectomy specimen cohorts, we found that TRIM24 expression predicts patients' risk to develop disease recurrence with high accuracy and independent from other established biomarkers. Further, this is the first study exploring TRIM24 expression on prostate needle biopsies which represents the clinically relevant tissue type on which biomarkers guide treatment decisions. Thus, we strongly suggest introducing TRIM24 evaluation in prostate needle biopsies in clinical routine as an inexpensive and simple immunohistochemical test. PMID: 31178279 [PubMed - as supplied by pub...
Source: Urologic Oncology - June 7, 2019 Category: Urology & Nephrology Authors: Offermann A, Roth D, Hupe MC, Hohensteiner S, Becker F, Joerg V, Carlsson J, Kuempers C, Ribbat-Idel J, Tharun L, Sailer V, Kirfel J, Svensson M, Andren O, Lubczyk V, Kuefer R, Merseburger AS, Perner S Tags: Urol Oncol Source Type: research

Trends and outcomes in contemporary management renal cell carcinoma and vena cava thrombus.
CONCLUSION: In select cases and experienced hands, robotic approach offers a reasonable alternative to open surgery without an increased complication rate. PMID: 31174956 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - June 5, 2019 Category: Urology & Nephrology Authors: Beksac AT, Shah QN, Paulucci DJ, Lo JZ, Okhawere KE, Elbakry AA, Dayal BD, Mehrazin R, Eun D, Hemal A, Abaza R, Sfakianos JP, Badani KK Tags: Urol Oncol Source Type: research

Impact of rhabdoid differentiation on postoperative outcome for patients with N0M0 renal cell carcinoma.
CONCLUSIONS: In summary, the aggressiveness of N0M0 RCC with RD increased the risk of postoperative recurrence, particularly in the early pathological stage. The short TTR also demonstrated the aggressiveness of RCC with RD. PMID: 31174957 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - June 5, 2019 Category: Urology & Nephrology Authors: Kim H, Inomoto C, Uchida T, Kajiwara H, Komiyama T, Kobayashi H, Nakamura N, Miyajima A Tags: Urol Oncol Source Type: research

Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
Abstract INTRODUCTION: Clinically, the papillary (pRCC) and chromophobe (chRCC) histologic subtypes of renal cell carcinoma (RCC) are viewed as more indolent compared to the more-common clear cell histology (ccRCC). However, there remain advanced cases of these purportedly less-aggressive histologies that lead to significant mortality. We therefore sought to evaluate outcomes of advanced pRCC and chRCC compared to ccRCC utilizing the National Cancer Database's registry of RCC patients. MATERIALS AND METHODS: A total of 115,365 ccRCC patients, 28,344 pRCC patients, and 11,942 chRCC patients met eligibility cri...
Source: Urologic Oncology - June 5, 2019 Category: Urology & Nephrology Authors: Kaldany A, Paulucci DJ, Kannappan M, Beksac AT, Anastos H, Okhawere K, Sfakianos JP, Badani KK Tags: Urol Oncol Source Type: research

Prognostic value and association with epithelial-mesenchymal transition and molecular subtypes of the proteoglycan biglycan in advanced bladder cancer.
Abstract OBJECTIVE: Dysregulation of the extracellular matrix molecule biglycan (BGN) predicts poor survival in several cancer entities. Our study investigated the prognostic impact of BGN in bladder cancer (BC) in 2 independent cohorts and assessed its role in epithelial-mesenchymal transition (EMT) and association with molecular BC subtypes. METHODS: BGN protein expression was correlated with the oncological outcome of 162 patients with BC undergoing radical cystectomy (RC) in a single center and furthermore on gene expression level in the TCGA database. Cut-off values for BGN protein and RNA expression wer...
Source: Urologic Oncology - June 5, 2019 Category: Urology & Nephrology Authors: Schulz GB, Grimm T, Sers C, Riemer P, Elmasry M, Kirchner T, Stief CG, Karl A, Horst D Tags: Urol Oncol Source Type: research

Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2.
oor A Abstract OBJECTIVE: To evaluate outcomes of surgically treated patients with clinically localized papillary renal cell carcinoma (RCC) and determine if papillary RCC subtype is associated with recurrence and survival. METHODS: This is a historical cohort study using the prospectively maintained Canadian Kidney Cancer Information System database between January 2011 and September 2018. All patients underwent partial or radical nephrectomy. Patient, tumor, treatment, and outcomes were compared between papillary RCC type 2 and type 1 cohorts. RESULTS: During the study period, 509 patients had clinical...
Source: Urologic Oncology - June 5, 2019 Category: Urology & Nephrology Authors: Wong ECL, Di Lena R, Breau RH, Pouliot F, Finelli A, Lavallée LT, So A, Tanguay S, Fairey A, Rendon R, Richard PO, Lattouf JB, Kawakami J, Mallick R, Kapoor A Tags: Urol Oncol Source Type: research

Genetic polymorphism and carbonic anhydrase 9 expression can predict nodal metastatic prostate cancer risk in patients with prostate-specific antigen levels ≤10 ng/ml at initial biopsy.
CONCLUSION: The rs3829078 polymorphic genotype of CA9 can predict the risk of lymph node metastasis of CaP with an initial PSA level ≤10 ng/ml. This is the first study to report a correlation between CA9 gene polymorphisms/CA9 mRNA expression and early detection of CaP. PMID: 31155437 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 31, 2019 Category: Urology & Nephrology Authors: Lin CY, Wang SS, Yang CK, Li JR, Chen CS, Hung SC, Chiu KY, Cheng CL, Ou YC, Yang SF Tags: Urol Oncol Source Type: research

Prognostic performance of the 1973 and 2004 WHO grading classification in upper tract urothelial carcinoma.
CONCLUSIONS: The results support the hypothesis that the 1973 WHO system is superior to the 2004 system for predicting clinical outcomes in patients with non-muscle-invasive UTUC. PMID: 31153747 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 30, 2019 Category: Urology & Nephrology Authors: Guan B, Tang S, Zhan Y, Li Y, Fang D, Peng D, Gong Y, He S, Zhang L, Yang K, Xiong G, Liu L, He Q, Li X, Zhou L Tags: Urol Oncol Source Type: research

Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma.
Abstract The last 30 years of research in renal cell carcinoma (RCC) has revealed that the vast majority of RCC histologies share a recurrent pattern of mutations to metabolic genes, including VHL, MTOR, ELOC, TSC1/2, FH, SDH, and mitochondrial DNA. This has prompted intense study of the consequences of these mutations on cellular metabolism and physiology in vivo by leveraging high-throughput technologies to measure small-molecule metabolites (i.e., metabolomics). The purpose of this review is to give a broad and integrated view on the discoveries made in RCC with metabolomics, and to give a basic understanding o...
Source: Urologic Oncology - May 30, 2019 Category: Urology & Nephrology Authors: DiNatale RG, Sanchez A, Hakimi AA, Reznik E Tags: Urol Oncol Source Type: research

Applying the PRECISION approach in biopsy na ïve and previously negative prostate biopsy patients.
Applying the PRECISION approach in biopsy naïve and previously negative prostate biopsy patients. Urol Oncol. 2019 May 29;: Authors: Wang NN, Teslovich NC, Fan RE, Ghanouni P, Leppert JT, Brooks JD, Ahmadi S, Sonn GA Abstract OBJECTIVES: The PRECISION trial provides level 1 evidence supporting prebiopsy multiparametric magnetic resonance imaging (mpMRI) followed by targeted biopsy only when mpMRI is abnormal [1]. This approach reduced over-detection of low-grade cancer while increasing detection of clinically significant cancer (CSC). Still, important questions remain regarding the reproducibilit...
Source: Urologic Oncology - May 29, 2019 Category: Urology & Nephrology Authors: Wang NN, Teslovich NC, Fan RE, Ghanouni P, Leppert JT, Brooks JD, Ahmadi S, Sonn GA Tags: Urol Oncol Source Type: research

A review of salvage treatment options for disease progression after radiation therapy for localized prostate cancer.
We report on the efficacy and adverse effects of the currently available local salvage modalities including salvage radical prostatectomy, high dose rate and low dose rate brachytherapy, cryotherapy, high intensity focused ultrasound, and stereotactic body RT. We additionally discuss diagnosis of oligometastatic disease on imaging and current approaches to treatment with either radiation or surgery. While a full review of chemotherapy and advanced androgen therapies is beyond the scope of this article we briefly discuss their use in the treatment of newly diagnosed recurrence after radiation. PMID: 31133370 [PubMed - ...
Source: Urologic Oncology - May 24, 2019 Category: Urology & Nephrology Authors: Steele EM, Holmes JA Tags: Urol Oncol Source Type: research

Significance of CLASP2 expression in prognosis for muscle-invasive bladder cancer patients: A propensity score-based analysis.
CONCLUSION: CLASP2 expression is correlated with malignant progression of MIBC. High CLASP2 expression predicted a poor prognosis for MIBC patients after RC-PLND. PMID: 31130343 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 23, 2019 Category: Urology & Nephrology Authors: Chen L, Xiong W, Guo W, Su S, Qi L, Zhu B, Mo M, Jiang H, Li Y Tags: Urol Oncol Source Type: research

Contemporary clinicopathological characteristics of pT0 prostate cancer at radical prostatectomy: A population-based study.
Abstract BACKGROUND: The incidence of pT0 prostate cancer (CaP) at radical prostatectomy (RP) is extremely rare. We performed the first population-based analysis of pT0 CaP at RP. METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2015), we tested for clinical and pathological characteristics according to pT0 vs. non-pT0 CaP and included a multivariable logistic regression model. RESULTS: pT0 was identified in 358 (0.2%) out of 160,532 clinically localized RP patients. The majority of pT0 patients presented with initial prostate-specific antigen (PSA)
Source: Urologic Oncology - May 22, 2019 Category: Urology & Nephrology Authors: Knipper S, Tilki D, Mazzone E, Mistretta FA, Palumbo C, Pecoraro A, Tian Z, Briganti A, Saad F, Graefen M, Karakiewicz PI Tags: Urol Oncol Source Type: research

Survival after radiotherapy vs. radical prostatectomy for unfavorable intermediate-risk prostate cancer.
CONCLUSION: We found no statistically significant difference in survival between RP and EBRT+BT. EBRT and brachytherapy had higher mortality, respectively, compared to RP. When including only radiotherapy patients who received ADT and, in the case of EBRT, a total dose ≥ 7920 cGy, there was no statistically significant difference in survival when comparing RP to EBRT or brachytherapy. These findings should be prospectively studied. PMID: 31109836 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 18, 2019 Category: Urology & Nephrology Authors: Sebastian NT, McElroy JP, Martin DD, Sundi D, Diaz DA Tags: Urol Oncol Source Type: research

The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer.
CONCLUSIONS: MIBC patients with pCR after NAC have improved conditional survival relative to those with pRD post-RC. This survival advantage does not significantly change over time. These findings may inform patient counseling, surveillance intensity, and novel adjuvant approaches for patients with pRD. PMID: 31109837 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 18, 2019 Category: Urology & Nephrology Authors: Waingankar N, Jia R, Marqueen KE, Audenet F, Sfakianos JP, Mehrazin R, Ferket BS, Mazumdar M, Galsky MD Tags: Urol Oncol Source Type: research

Management of high complexity renal masses in partial nephrectomy: A multicenter analysis.
Abstract OBJECTIVE: To determine the safety and efficacy of performing partial nephrectomy (PN) on patients with high nephrometry score tumors. PATIENTS AND METHODS: We used a prospectively maintained multi-institutional kidney cancer database to identify 144 patients with R.E.N.A.L. nephrometry score ≥10 who underwent PN for a cT1-cT2 renal mass. Baseline demographics and clinical characteristics, tumor characteristics, perioperative, and pathological outcomes were analyzed and reported. Trifecta achievement, defined by warm ischemia time
Source: Urologic Oncology - May 16, 2019 Category: Urology & Nephrology Authors: Beksac AT, Okhawere KE, Elbakry AA, Dayal BD, Paulucci DJ, Rothberg MB, Sfakianos JP, Abaza R, Eun DD, Bhandari A, Hemal AK, Porter J, Badani KK Tags: Urol Oncol Source Type: research

Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer.
Abstract OBJECTIVE: Our aim was to evaluate the usefulness of serum testosterone to guide treatment decision for castration-resistant prostate cancer (CRPC). METHODS: We conducted a retrospective analysis of 115 patients with CRPC treated with either abiraterone (n = 43) or enzalutamide (n = 72). A serum testosterone level was measured at time of starting of abiraterone or enzalutamide. We determined whether serum testosterone influenced the outcomes of androgen receptor (AR)-targeted therapy. RESULTS: In the very-low testosterone group (
Source: Urologic Oncology - May 16, 2019 Category: Urology & Nephrology Authors: Hashimoto K, Tabata H, Shindo T, Tanaka T, Hashimoto J, Inoue R, Muranaka T, Hotta H, Yanase M, Kunishima Y, Takahashi A, Masumori N, Sapporo Medical University Urologic Oncology Consortium (SUOC) Tags: Urol Oncol Source Type: research

Urologic oncology workforce diversity: A first step in reducing cancer disparities.
Abstract Urologic cancer disparities based on race/ethnicity and gender are well-documented across the cancer continuum. Patients cared for by physicians of similar race/ethnicity and gender report better communication, patient satisfaction, and care adherence which has the potential to translate into better health outcomes. We believe that ensuring a diverse Urologic Oncology workforce is an important first step toward eliminating cancer disparities due to the downstream effects of improved communication between concordant patient-physician dyads. In this essay, we review the demographics of the Urologic cancer p...
Source: Urologic Oncology - May 16, 2019 Category: Urology & Nephrology Authors: Garg T, Antar A, Taylor JM Tags: Urol Oncol Source Type: research

Cardiovascular toxicities of therapy for genitourinary malignancies.
Abstract The cardiovascular consequences of systemic cancer therapies are becoming increasingly important for the growing population of patients living with cancer. In particular, patients with genitourinary malignancies are at significant risk for cardiovascular toxicities, due to both prevalent underlying risk factors and the known adverse effects of commonly used therapies. Moreover, improving survival outcomes and novel combination treatment approaches for genitourinary malignancies may predispose to a growing risk for cardiovascular morbidity. As such, knowledge of these potential cardiovascular risks is esse...
Source: Urologic Oncology - May 16, 2019 Category: Urology & Nephrology Authors: Narayan V, Vaughn DJ, Ky B Tags: Urol Oncol Source Type: research

Human urothelial bladder cancer generates a clonal immune response: The results of T-cell receptor sequencing.
CONCLUSIONS: Primary urothelial tumors contain clonally expanded T-cell populations. These data support the hypothesis that bladder tumors induce an antigen-driven immunogenic host response, in contrast to the benign inflammatory response, which does not appear to demonstrate any T-cell clonal dominance. PMID: 31103336 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 15, 2019 Category: Urology & Nephrology Authors: Sankin A, Chand D, Schoenberg M, Zang X Tags: Urol Oncol Source Type: research

Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study.
Abstract BACKGROUND: Marital status rates may have changed over time in prostate cancer (PC) patients and may have affected cancer-specific mortality (CSM) and other-cause mortality (OCM). METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2015), we identified PC patients who were either married (n = 326,664) or unmarried (n = 106,533). Temporal trends, cumulative incidence plots, as well as multivariable competing risks regression analyses focused on (1) the overall population, (2) D'Amico low-risk N0M0 PC, (3) D'Amico intermediate-risk N0M0 PC, (4) D'Amico high-risk N0M0 ...
Source: Urologic Oncology - May 15, 2019 Category: Urology & Nephrology Authors: Knipper S, Preisser F, Mazzone E, Mistretta FA, Palumbo C, Tian Z, Briganti A, Shariat SF, Saad F, Tilki D, Graefen M, Karakiewicz PI Tags: Urol Oncol Source Type: research

Socioeconomic and insurance status are independent prognostic indicators of higher disease stage and worse prognosis in bladder cancer.
The objective of this study was to determine the effect of SES and insurance type on outcomes in bladder cancer. MATERIALS AND METHODS: A population-based search was performed using the National Cancer Institute's Surveillance, Epidemiology, and End Results 18 database. Patients aged 18 or older and diagnosed with bladder cancer between 2011 and 2015 were identified. Data on patient demographics, SES features, insurance status, tumor characteristics, and survival were collected. A county-level SES measure was created in a method consistent with prior literature. Primary outcomes were overall survival (OS) and disease-...
Source: Urologic Oncology - May 8, 2019 Category: Urology & Nephrology Authors: Nazemi A, Ghodoussipour S, Pearce S, Bhanvadia S, Daneshmand S Tags: Urol Oncol Source Type: research

Low awareness, adherence, and practice but positive attitudes regarding lifestyle recommendations among non-muscle-invasive bladder cancer patients.
CONCLUSIONS: These findings show that awareness of (bladder) cancer risk factors and adherence to cancer prevention lifestyle recommendations among NMIBC patients is low and that physicians' information provision should be improved. PMID: 31076356 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 8, 2019 Category: Urology & Nephrology Authors: Westhoff E, Kampman E, Aben KK, Hendriks IG, Witjes JA, Kiemeney LA, Vrieling A Tags: Urol Oncol Source Type: research

Predicting acute kidney injury after robot-assisted partial nephrectomy: Implications for patient selection and postoperative management.
Abstract BACKGROUND: Acute Kidney Injury (AKI) is a common occurrence after partial nephrectomy and is a significant risk factor for chronic kidney disease. We aimed to create a model that predicts postoperative AKI in patients undergoing robot-assisted partial nephrectomy (RAPN). METHODS: We identified 1,190 patients who underwent RAPN between 2008 and 2017 from a multicenter database. AKI was defined as a>25% reduction in eGFR from pre-RAPN to discharge. A nomogram was built based on a binary logistic regression that ultimately included age, sex, BMI, diabetes, baseline eGFR, and RENAL Nephrometry score....
Source: Urologic Oncology - May 7, 2019 Category: Urology & Nephrology Authors: Martini A, Sfakianos JP, Paulucci DJ, Abaza R, Eun DD, Bhandari A, Hemal AK, Badani KK Tags: Urol Oncol Source Type: research

Role of novel imaging in the management of prostate cancer.
Abstract This review summarizes novel imaging in the management of prostate cancer including multiparametric MRI, PET-CT scans with different radiotracers including 11C-acetate, 11C-choline, 18F-choline, 18F sodium fluoride, prostate-specific membrane antigen, and anti-1-amino-3-[18F] fluorocyclobutane-1-carboxylic acid (fluciclovine). PMID: 31072791 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 6, 2019 Category: Urology & Nephrology Authors: Xu KM, Chen RC, Schuster DM, Jani AB Tags: Urol Oncol Source Type: research

The current state of randomized clinical trial evidence for prostate brachytherapy.
Abstract Interstitial brachytherapy is one of several curative therapeutic options for the treatment of localized prostate cancer. In this review, we summarize all available randomized data to support the optimal use of prostate brachytherapy. Evidence from completed randomized controlled trials is the focus of this review with a presentation also of important ongoing trials. Gaps in knowledge are identified where future investigation may be fruitful with intent to inspire well-designed prospective studies with standardized treatment that focuses on improving oncological outcomes, reducing morbidity, or maintainin...
Source: Urologic Oncology - May 3, 2019 Category: Urology & Nephrology Authors: Dess RT, Soni PD, Jackson WC, Berlin A, Cox BW, Jolly S, Efstathiou JA, Feng FY, Kishan AU, Stish BJ, Pisansky TM, Spratt DE Tags: Urol Oncol Source Type: research

BioScore (B7-H1, survivin, and Ki-67) does not predict cancer-specific mortality in surgically treated patients with renal cell carcinoma: An external validation study.
CONCLUSION: Although a higher BioScore was significantly associated with a higher CSM, the magnitude of this association was weak and not independent from other prognosticators. Moreover, BioScore did not improve the prognostic accuracy of the SSIGN score. PMID: 31060796 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 3, 2019 Category: Urology & Nephrology Authors: Hutterer GC, Posch F, Buser L, Zigeuner R, Morshäuser L, Otto W, Wild PJ, Burger M, May M, Pichler M, Brookman-May SD Tags: Urol Oncol Source Type: research

Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival.
CONCLUSIONS: In the present large population-based cystectomy series, LVI and clinical stage were independently associated with CSS. However, molecular subtypes determined by global gene expression showed no such association with CSS according to either the Consensus molecular subtypes of muscle-invasive bladder cancer or Lund taxonomy. PMID: 31056435 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 2, 2019 Category: Urology & Nephrology Authors: Kollberg P, Chebil G, Eriksson P, Sjödahl G, Liedberg F Tags: Urol Oncol Source Type: research

The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals?
Abstract BACKGROUND: A considerable number of prostate cancer (PCa) patients eligible for expectant management receive definitive treatment. We aimed to investigate the hospital-level contribution to overtreatment in the United States. METHODS: Using the National Cancer Database we identified two nonoverlapping cohorts: (1) men with a life expectancy
Source: Urologic Oncology - May 2, 2019 Category: Urology & Nephrology Authors: Krimphove MJ, Cole AP, Friedlander DF, Nguyen DD, Lipsitz SR, Nguyen PL, Kilbridge KL, Kibel AS, Kluth LA, Trinh QD Tags: Urol Oncol Source Type: research

Updates in the molecular epidemiology and systemic approaches to penile cancer.
Abstract Penile cancer is a rare, but increasingly more common diagnosis. Although more there are more cases of penile cancer being diagnosed (the incidence is increasing), mortality (or conversely overall survival) has not changed. A detailed discussion of current treatments, along with potential therapeutic targets, and ongoing clinical trials is presented. This review gives insight to treatment strategies and novel modalities to combat a disease with sparse therapeutic options. PMID: 31053523 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 1, 2019 Category: Urology & Nephrology Authors: Adashek JJ, Necchi A, Spiess PE Tags: Urol Oncol Source Type: research

Preoperative plasma IGFBP2 is associated with nodal metastasis in patients with penile squamous cell carcinoma.
Abstract PURPOSE: The nodal status is a strong predictor for clinical outcome in patients with penile cancer. We aimed to evaluate the association between preoperative plasma IGFBP2 levels and nodal status in patients with penile squamous cell carcinoma (PSCC). METHODS: This retrospective study enrolled 56 penile cancer patients who underwent penectomy between 2015 and 2017. Preoperative plasma IGFBP2 levels were detected by enzyme linked immunosorbent assay, which was analyzed in association with clinicopathological parameters (age, body mass index, pathological grade, phimosis, histological subtype, tumor s...
Source: Urologic Oncology - April 30, 2019 Category: Urology & Nephrology Authors: Hu X, Chen M, Liu W, Li Y, Fu J Tags: Urol Oncol Source Type: research

Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter study.
Abstract OBJECTIVES: To improve the prognostic allocation of patients with penile squamous-cell carcinoma (PSCC) receiving regional lymph node dissection (LND). PATIENTS AND METHODS: An international, multicenter, retrospective study was performed on patients with PSCC who received regional LND, with or without perioperative therapy, from 1980 to 2017. We first used a random forest (RF) method with missing data imputation. Additionally, data were modeled using Cox proportional hazard regression, and a Cox model was also fit including prespecified variables. Based on the latter model, a nomogram for estimating...
Source: Urologic Oncology - April 30, 2019 Category: Urology & Nephrology Authors: Necchi A, Lo Vullo S, Mariani L, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ager M, Hakenberg OW, Heidenreich A, Raggi D, Catanzaro M, Salvioni R, Chipollini J, Azizi M, Spiess PE Tags: Urol Oncol Source Type: research

Noncaseating granulomatous diseases in germ cell cancer patients-A single-center experience.
CONCLUSIONS: In GCT patients, the coexistence of noncaseating granulomatous disease is common. Minimal invasive bronchoscopic techniques can serve for the cytopathologic exclusion of malignant thoracic manifestations. In our monocenter patient group the coexistence of SLL did not have any prognostic impact on overall survival. PMID: 31053525 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - April 30, 2019 Category: Urology & Nephrology Authors: Schmidt LH, Huss S, Schuelke C, Schulze A, Evers G, Schliemann C, Hansmeier A, Schilling B, Lauterbach B, Barth P, Wiebe K, Goerlich D, Berdel WE, Puehse G, Mohr M Tags: Urol Oncol Source Type: research

Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer.
CONCLUSIONS: Our results demonstrate that survivin represents a promising marker for the prediction of cisplatin resistance in BC. In addition the therapy predictive role of HMGA2 should be further investigated. Immunohistochemical analysis of BC samples provides a feasible way for the prediction of cisplatin-resistance and may therefore provide a valuable tool for optimizing treatment decisions in advanced BC. PMID: 31053526 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - April 30, 2019 Category: Urology & Nephrology Authors: Krafft U, Tschirdewahn S, Hess J, Harke NN, Hadaschik B, Olah C, Krege S, Nyirády P, Szendröi A, Szücs M, Módos O, Székely E, Reis H, Szarvas T Tags: Urol Oncol Source Type: research

Immunohistochemical expression of CD44, matrix metalloproteinase2 and matrix metalloproteinase9 in renal cell carcinomas.
Abstract PURPOSE: The aim of our study was to investigate the clinicopathologic values of the expression of CD44, matrix metalloproteinase (MMP)2, and MMP9 in renal cell carcinoma (RCC). PATIENTS AND METHODS: A total of 107 clear cell RCCs (ccRCCs) and 32 nonclear cell RCCs (non-ccRCCs) were examined for CD44, MMP2, and MMP9 expression by immunohistochemistry. The membrane and cytoplasmic expression levels of the 3 proteins were scored by semiquantitative methods, and the correlations of the 3 proteins with clinicopathological parameters were verified. RESULTS: The expression levels of CD44, MMP2, and MM...
Source: Urologic Oncology - April 30, 2019 Category: Urology & Nephrology Authors: Lee YM, Kim JM, Lee HJ, Seong IO, Kim KH Tags: Urol Oncol Source Type: research

C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma - A data from multi-institutional study in Japan.
The objective in the study is to examine the prognostic value of CAR in patients with RCC who underwent nephrectomy. MATERIAL AND METHODS: The record data from multi-institutional study of 1,028 patients was analyzed in the study. The cut-off value of the CAR was defined by receive operating characteristic (ROC) analysis. Overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) were evaluated, and univariate and multivariate analyses were conducted to assess the predictive value of the variables including CAR. RESULT: The optimal cut-off value of 0.073 in CAR was defined according...
Source: Urologic Oncology - April 30, 2019 Category: Urology & Nephrology Authors: Tsujino T, Komura K, Hashimoto T, Muraoka R, Satake N, Matsunaga T, Tsutsumi T, Yoshikawa Y, Takai T, Minami K, Uehara H, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Ohno Y, Azuma H Tags: Urol Oncol Source Type: research

Communicative aspects of decision aids for localized prostate cancer treatment - A systematic review.
CONCLUSIONS: Our review suggests that DAs for LPC treatment could be further improved by adding CAs such as personalized outcome predictions and interaction methods to the DAs. Clinicians who are using or developing such tools might therefore consider these CAs in order to enhance patient participation in treatment decision-making. PMID: 31053529 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - April 30, 2019 Category: Urology & Nephrology Authors: Vromans RD, van Eenbergen MC, Pauws SC, Geleijnse G, van der Poel HG, van de Poll-Franse LV, Krahmer EJ Tags: Urol Oncol Source Type: research

Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer.
Abstract INTRODUCTION: Contemporary guidelines recommend cystectomy with neoadjuvant or adjuvant cisplatin-based chemotherapy given with curative intent for patients with resectable muscle-invasive bladder cancer (MIBC). However, rates and appropriateness of perioperative chemotherapy utilization remain unclear. We therefore sought to characterize use of perioperative chemotherapy in older radical cystectomy MIBC patients and examine factors associated with use. METHODS: Using Surveillance, Epidemiology, and End Results (SEER)-Medicare data, we identified patients with MIBC diagnosed between 2004 and 2013 and...
Source: Urologic Oncology - April 30, 2019 Category: Urology & Nephrology Authors: Macleod LC, Yabes JG, Yu M, Fam MM, Hale NE, Turner RM, Lopa SH, Gingrich JR, Borza T, Skolarus TA, Davies BJ, Jacobs BL Tags: Urol Oncol Source Type: research

Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy.
t P Abstract OBJECTIVES: Cancer survivors are often diagnosed with subsequent prostate cancer. To improve medical care of these patients, we examined the oncological outcomes in men with prostate cancer and a cancer history. PATIENTS AND METHODS: We retrospectively analyzed data from 25,422 prostate cancer patients, who underwent a radical prostatectomy between 1992 and 2016. Patients with other malignancies were identified using medical records and self-administrated questionnaires. Cox regression and Kaplan Meier analysis of a propensity score-matched patient cohort were performed to examine biochemical rec...
Source: Urologic Oncology - April 30, 2019 Category: Urology & Nephrology Authors: Klippenstein P, Schlomm T, von Amsberg G, Beyer B, Pompe RS, Michl U, Salomon G, Thederan I, Budäus L, Heinzer H, Tilki D, Haese A, Huland H, Graefen M, Steuber T, Tennstedt P Tags: Urol Oncol Source Type: research

NK and T cells with a cytotoxic/migratory phenotype accumulate in peritumoral tissue of patients with clear cell renal carcinoma.
CONCLUSIONS: The cytotoxic/migratory lymphocytes were identified in tumors of ccRCC patients. These lymphocytes became excluded from the tumor and accumulated in the patient's peritumoral tissue. PMID: 31030972 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - April 26, 2019 Category: Urology & Nephrology Authors: Strizova Z, Taborska P, Stakheev D, Partlová S, Havlova K, Vesely S, Bartunkova J, Smrz D Tags: Urol Oncol Source Type: research

Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder.
CONCLUSIONS: A high percentage of the bladder tumors from male patients in our cohort expressed AR. The combination of Enz and Cis synergistically inhibited growth of BCa cells more efficiently than single agent alone. This supports the rationale for future investigation of AR antagonists in combination with standard chemotherapy in MIBC. PMID: 31006613 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - April 18, 2019 Category: Urology & Nephrology Authors: Tyagi A, Chandrasekaran B, Kolluru V, Rai S, Jordan AC, Houda A, Messer J, Ankem M, Damodaran C, Haddad A Tags: Urol Oncol Source Type: research

sE-cadherin is upregulated in serum of patients with renal cell carcinoma and promotes tumor cell dissemination in vitro.
CONCLUSIONS: sE-cadherin is overexpressed in serum of RCC patients and provides a functional cellular switch from sessility to aggressive dissemination. While sE-cadherin is not tumor-specific and thus inappropriate for population-based screening, further studies are warranted to investigate its role in monitoring RCC and employing it as a therapeutic target. PMID: 31005422 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - April 18, 2019 Category: Urology & Nephrology Authors: Tsaur I, Hüsch T, Jüngel E, Schneider F, Schneider M, Haferkamp A, Thomas C, Lieb V, Wach S, Taubert H, Chun FK, Blaheta RA Tags: Urol Oncol Source Type: research

A propensity score matched analysis of the effects of African American race on the characteristics of regions of interests detected by magnetic resonance imaging of the prostate.
Abstract OBJECTIVES: To evaluate the effects of African American (AA) race on the number, location, Prostate Imaging Reporting and Data System (PI-RADS) score, cancer detection rate, and cancer upgrade rate of the regions of interest (ROI) discovered on mltiparametric magnetic resonance imaging (mp-MRI) of the prostate. METHODS: We performed an institutional retrospective study of 592 patients who received a prostate mp-MRI. Number of ROI (1-4), their location, and PI-RADS score v2 were evaluated in a matched cohort of Caucasian and AA males. Propensity score matching was performed using the variables of age,...
Source: Urologic Oncology - April 17, 2019 Category: Urology & Nephrology Authors: Deebajah M, Keeley J, Park H, Pantelic M, Gupta N, Williamson SR, Peabody J, Menon M, Dabaja A, Alanee S Tags: Urol Oncol Source Type: research

mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy.
CONCLUSION: mpMRI proved reliable in detecting lesion changes after antiandrogen therapy corresponding to PCa pathology. Therefore, mpMRI of treated prostates may be helpful for assessing men for surgical planning and staging. PMID: 31000430 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - April 15, 2019 Category: Urology & Nephrology Authors: Gold SA, VanderWeele DJ, Harmon S, Bloom JB, Karzai F, Hale GR, Marhamati S, Rayn KN, Mehralivand S, Merino MJ, Gulley JL, Bilusic M, Madan RA, Choyke PL, Turkbey B, Dahut W, Pinto PA Tags: Urol Oncol Source Type: research

Diagnostic and prognostic value of the detection of hTERT mRNA in renal tumors.
az-Piqueras Á, Salinas-Sánchez AS Abstract INTRODUCTION: Elevated mRNA expression of human telomerase reverse transcriptase (hTERT mRNA) is common in many types of tumors, participating in tumor growth and progression. Such expression has not been sufficiently examined in renal cancer. The goal of the present study was to quantify it and analyze its possible clinical value in the management of this pathology. PATIENTS AND METHODS: The study included 111 patients who underwent surgery for renal cell carcinoma (RCC) between 2015 and 2017. Tumor samples were taken from all patients and, in 94 of th...
Source: Urologic Oncology - April 8, 2019 Category: Urology & Nephrology Authors: Martínez-Sanchíz C, García-Olmo DC, Picazo-Martínez MG, Nam-Cha SY, Giménez-Bachs JM, Flores-Bautista AB, Díaz-Piqueras Á, Salinas-Sánchez AS Tags: Urol Oncol Source Type: research

The prognostic value of zonal origin and extraprostatic extension of prostate cancer for biochemical recurrence after radical prostatectomy.
CONCLUSION: TZ cancer had more favorable pathological characteristics and oncological outcome than PZ cancer especially in pT3a cases. PMID: 30967332 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - April 6, 2019 Category: Urology & Nephrology Authors: Takamatsu K, Matsumoto K, Shojo K, Tanaka N, Takeda T, Morita S, Kosaka T, Mizuno R, Shinojima T, Kikuchi E, Asanuma H, Oya M Tags: Urol Oncol Source Type: research